Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24035689 | 0.87 | DGAT1 (0.37) | SMN1; SMN2MAPTALDH1A1DGAT1ELANE | |
| SCHEMBL25414258 | 0.87 | SMN1; SMN2 (0.41) | TDP1SMN1; SMN2POLBRAB9AL3MBTL1 | |
| SCHEMBL22900763 | 0.86 | SMN1; SMN2 (0.41) | TDP1SMN1; SMN2POLBRAB9AL3MBTL1 | |
| SCHEMBL25107980 | 0.86 | TDP1 (0.40) | TDP1SMN1; SMN2POLBRAB9AL3MBTL1 | |
| SCHEMBL30871782 | 0.86 | TDP1 (0.45) | TDP1SMN1; SMN2POLBRAB9AL3MBTL1 | |
| SCHEMBL24298797 | 0.85 | TDP1 (0.39) | TDP1SMN1; SMN2POLBRAB9AL3MBTL1 | |
| SCHEMBL20854943 | 0.85 | TDP1 (0.40) | TDP1SMN1; SMN2POLBRAB9AL3MBTL1 | |
| SCHEMBL31021743 | 0.85 | SMN1; SMN2 (0.41) | TDP1SMN1; SMN2POLBRAB9AL3MBTL1 | |
| SCHEMBL20140164 | 0.85 | TDP1 (0.39) | TDP1SMN1; SMN2POLBRAB9AL3MBTL1 | |
| SCHEMBL17592980 | 0.84 | DGAT1 (0.38) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145597-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2025045746-A1 | PYRAZOLE DERIVATIVES AS SARM1 INHIBITORS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2025-03-06 | — | — | WO | disclosed |
| US-12233065-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4479138-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | Accent Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12162867-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240316047-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20240279210-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240116912-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | TERNS PHARMACEUTICALS, INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4271377-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | Terns Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-116887827-A | Compounds and methods for modulating FXR | 拓臻制药公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2022147448-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | TERNS PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2016040449-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316047-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX29, DHX9, DDX39B | TDP1 243/4885SMN1; SMN2 662/4885POLB 79/4885 |
| US-20240279210-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX29, DHX9, DDX39B | TDP1 258/4885SMN1; SMN2 536/4885POLB 160/4885 |
| US-12233065-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | DHX29, DHX9, DDX39B | TDP1 243/4885SMN1; SMN2 662/4885POLB 79/4885 |
| US-12162867-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | DHX29, DHX9, DDX39B | TDP1 258/4885SMN1; SMN2 536/4885POLB 160/4885 |
| US-20240116912-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, FXR2 | TDP1 4710/4885SMN1; SMN2 4878/4885POLB 3424/4885 |
| US-20250145597-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX9, DHX29, DDX39B | TDP1 165/4885SMN1; SMN2 645/4885POLB 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.